Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun:137:108690.
doi: 10.1016/j.jsat.2021.108690. Epub 2021 Dec 13.

Treatment preference for opioid use disorder among people who are incarcerated

Eliana Kaplowitz  1 , Ashley Q Truong  2 , Justin Berk  3 , Rosemarie A Martin  4 , Jennifer G Clarke  5 , Morgan Wieck  5 , Josiah Rich  6 , Lauren Brinkley-Rubinstein  7
Affiliations

Treatment preference for opioid use disorder among people who are incarcerated

Eliana Kaplowitz et al. J Subst Abuse Treat. 2022 Jun.

Abstract

Introduction: The devastating overdose crisis remains a leading cause of death in the United States, especially among individuals involved in the criminal legal system. Currently, three classes (opioid agonist, partial agonist-antagonist, and antagonist) of FDA-approved medications for opioid use disorder (MOUD) exist, yet few correctional settings offer any medication treatment for people who are incarcerated. Facilities that do often provide only one medication.

Methods: We conducted 40 semi-structured qualitative interviews with individuals receiving MOUD incarcerated at the Rhode Island Department of Corrections.

Results: Results from this study indicate that people who are incarcerated have preferences for certain types of MOUD. Individuals' preferences were influenced by medication side effects, route of administration, delivery in the community, and stigma.

Conclusion: MOUD programs in the community and in correctional settings should use a patient-centered approach that allows choice of medication by offering all FDA-approved MOUD treatment options.

Keywords: Incarceration; Medication for opioid use disorder; Opioid use disorder; Patient preference.

PubMed Disclaimer

References

    1. Binswanger IA, Blatchford PJ, Mueller SR, & Stern MF (2013). Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. 10.7326/0003-4819-159-9-201311050-00005 - DOI - PMC - PubMed
    1. Brinkley-Rubinstein L, Peterson M, Clarke J, Macmadu A, Truong A, Pognon K, Parker M, Marshall BDL, Green T, Martin R, Stein L, & Rich JD (2019). The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug and Alcohol Dependence, 205, 107514. 10.1016/j.drugalcdep.2019.06.016 - DOI - PMC - PubMed
    1. Center for Disease Control. (2021, January 26). Pharmacogenomics: What does it mean for your health? https://www.cdc.gov/genomics/disease/pharma.htm
    1. Cioe K, Biondi BE, Easly R, Simard A, Zheng X, & Springer SA (2020). A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment, 119, 108146. 10.1016/j.jsat.2020.108146 - DOI - PMC - PubMed
    1. Clarke JG, Martin RA, Gresko SA, & Rich JD (2018). The First Comprehensive Program for Opioid Use Disorder in a US Statewide Correctional System. American Journal of Public Health, 108(10), 1323–1325. PubMed. 10.2105/AJPH.2018.304666 - DOI - PMC - PubMed

Publication types